Indegene will work with ConTIPI to drive revenue and ensure predictable cash outflow. The device has a 510(k) clearance from the FDA for marketing in the USA and has been granted the CE mark for marketing in Europe.ĬonTIPI’s expanded agreement with Indegene includes several services across the commercialization process, including sales, PRMA (pricing, reimbursement and market access), medical affairs, medical communications, pharmacovigilance, regulatory, marketing and commercial operations support. This innovation empowers women to take control over their own treatment. The current treatment methods include largely either invasive surgery with up to a 30% failure rate or the use of non-invasive pessaries which currently require a physician’s care to insert and remove and are associated with various adverse events.ĬonTIPI’s ProVate is a ready-to-use device that is inserted vaginally by the user thanks to an easy-to-use applicator, very similar to a menstrual tampon. Approximately 54 million American women over 20 years old suffer from POP 1. The US FDA states that POP occurs when the pelvic floor’s tissues and muscles can no longer support its organs which causes a drop or prolapse of the pelvic organs. and ISRAEL, (GLOBE NEWSWIRE) - Indegene, a digital-first, life sciences commercialization company announced today that it will be expanding its partnership with ConTIPI Medical Ltd, an innovator in the field of providing non-surgical and disposable solutions for women with various pelvic floor disfunctions, to bring a new device to the market.ĬonTIPI Medical’s mission is to help women suffering from Pelvic Organ Prolapse (POP).
Companies are also actively evaluating and deploying technology in various patient use cases."Īccording to Indegene, citing the Taking the Pulse 2018 study by DRG, healthcare professionals (HCP) engagement transformation is pegged at $2 billion and, along with patient experience management transformation, it is a $8-billion market opportunity in the near future.Īlistair Macdonald, CEO, Syneos Health, said: “We’re excited to partner with Omnipresence the innovative platform, underpinned by Microsoft technologies, to address customer demand to drive high-value commercial relationships in an increasingly competitive marketplace.PRINCETON, N.J. “One of the big areas is customer-engagement. Gupta said pharma and life sciences companies have been adopting technology rapidly. We will also accelerate the buildout of the patient cloud."
“We plan to increase our market presence, and will hire sales and marketing professionals across the world, primarily in the US and Europe. In a telephone interview, Gupta added that the funds will be used “primarily for market expansion and for extending the product". “This investment will further accelerate the roadmap and deployments of our customer experience management platform for life sciences and healthcare clients," Manish Gupta, co-founder and CEO, Indegene, said, in the statement. Omnipresence is a customer experience platform for healthcare and life sciences organisations with customer relationship management (CRM), omnichannel engagement, advanced analytics and artificial intelligence (AI) capabilities.
0 kommentar(er)
